Form 4: CorMedix Director Buys 25,000 Shares
Insider Transaction Report
CorMedix Inc. Director Myron Kaplan purchased 25,000 shares of common stock at a weighted average price of $11.02 on October 23, 2025.
Summary
- Director Myron Kaplan acquired 25,000 shares of CorMedix Inc. common stock.
- The transaction occurred on October 23, 2025.
- The shares were purchased at a weighted average price of $11.02, with individual transactions ranging from $11.01 to $11.03.
- Following this transaction, Myron Kaplan directly beneficially owns 201,034 shares.
- Myron Kaplan also indirectly holds 20,000 shares through his spouse and 10,000 shares through his spouse as guardian for grandchildren, though he disclaims beneficial ownership of these indirect holdings.
Sentiment
Score: 8
Explanation: The director's open market purchase of a substantial number of shares signals strong insider confidence in the company's future prospects and current valuation.
Positives
- A director's open market purchase of 25,000 shares indicates confidence in the company's future prospects and current valuation.
Future Outlook
NA
Management Comments
- The reporting person disclaims beneficial ownership of these securities [indirectly held], and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Industry Context
NA
Stakeholder Impact
- Shareholders may view the director's purchase as a positive signal, potentially increasing investor confidence in CorMedix Inc.
Key Dates
| Date | Description |
|---|---|
| 10/23/2025 | Date of earliest transaction (common stock purchase) |
| 10/27/2025 | Signature date of the reporting person, Myron Kaplan |
Recommendation
buyThe significant open market purchase by a director, Myron Kaplan, at a weighted average price of $11.02 per share, signals strong insider confidence in CorMedix Inc.'s future prospects and current valuation. Such an action by a knowledgeable insider often precedes positive developments or reflects a belief that the stock is undervalued, making it a compelling 'buy' signal for investors.
Keywords
CorMedix, CRMD, insider trading, director purchase, stock acquisition, Form 4, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.